The RhoA GTPase is crucial in numerous biological functions and is linked to cancer metastasis. However, the understanding of the molecular mechanism responsible for RhoA transcription is still very limited. Here we show that RhoA transcription is orchestrated by the Myc-Skp2-Miz1-p300 transcriptional complex. Skp2 cooperates with Myc to induce RhoA transcription by recruiting Miz1 and p300 to the RhoA promoter independently of Skp1-Cullin-F-box protein containing complex (SCF)-Skp2 E3 ligase activity. Deficiency of this complex results in impairment in RhoA expression, cell migration, invasion, and breast cancer metastasis, recapitulating the phenotypes observed in RhoA knockdown, and RhoA restoration rescues the defect in cell invasion. Overexpression of the Myc-Skp2-Miz1 complex is found in metastatic human cancers and is correlated with RhoA expression. Our study provides insight into how oncogenic Skp2 and Myc coordinate to induce RhoA transcription and establishes a novel SCFSkp2 E3-ligase-independent function for oncogenic Skp2 in transcription and cancer metastasis.
. It causes most of the deaths of patients with cancer, and the treatment of this devastating form of disease remains a big challenge.
RhoA, a well-known member of the Rho family of GTPases, regulates numerous biological functions and is implicated in cancer metastasis 3, 4 . Although mutation of RhoA has not been found in human cancers [4] [5] [6] , upregulation of RhoA mRNA and RhoA protein levels have been well documented in various human cancers [7] [8] [9] . Moreover, RhoA overexpression overcomes senescence checkpoints and induces preneoplastic transformation of human mammary epithelial cells 10 , whereas RhoA deficiency suppresses the invasiveness of breast cancer cells 11 . A recent study also demonstrated that microRNA-31 (miR-31) suppresses breast cancer metastasis partly through downregulation of RhoA gene expression 12 . Although accumulating evidence unequivocally shows that RhoA overexpression is positively correlated with cancer metastasis 13, 14 , the transcription machinery responsible for RhoA gene expression has so far been unknown.
The Myc transcription factor heterodimerizes with Max and binds to the E-box motif CACGTG to activate transcription by cooperating with multiple coactivator complexes [15] [16] [17] . It serves a master regulator in various biological functions and is linked to metastasis. Recent studies demonstrate that Myc ubiquitylation is critical in Myc transcriptional activation in a subset of target genes that are important for cell proliferation [18] [19] [20] . Although a handful of Myc target genes involved in Myc-driven cell-cycle progression and apoptosis have been identified, its target genes responsible for Myc-mediated cell migration and metastasis still remain elusive.
In this study we sought to identify the transcription machinery critical for RhoA transcription and cancer metastasis. Our study reveals that the Myc-Skp2-Miz1 transcriptional complex is critical for RhoA gene transcription, cell invasion and cancer metastasis.
RESulTS

Myc serves a transcription factor for RhoA
To explore the transcriptional machinery for RhoA, we analysed the 5´ sequence upstream of the transcription start site up to 9 kilobase pairs (kb) with the computer program TFSEARCH (http://www.cbrc.jp/research/db/ TFSEARCH.html). We found that there is one canonical (CACGTG) and five non-canonical (CACGCG) E-boxes present within 2 kb upstream of transcription start site (Fig. 1a) , reminiscent of the binding sites for Myc and Twist 17, 21, 22 . Myc and Twist contribute to multiple steps of tumorigenesis and are linked to cancer metastasis 16, [21] [22] [23] [24] . To determine the role of Myc and Twist in RhoA transcription, we cloned this human RhoA promoter fragment (nucleotides −1850 to +1) into the pGL3 luciferase vector for a luciferase activity assay. RhoA transcriptional activity and protein expression were induced by Myc overexpression but not by Twist overexpression ( Fig. 1a; Supplementary Information, Fig. S1a, b) . This result suggests that RhoA transcription is selectively induced by Myc.
To dissect the promoter region required for RhoA transcription by Myc, we generated two fragments from the full-length RhoA promoter. To our surprise, the transcriptional activity of the distal region (fragment B) containing the canonical E-box motif was not induced by Myc, whereas the transcriptional activity of fragment C containing five non-canonical E-box motifs was readily induced by Myc (Fig. 1b) , suggesting that Myc may affect RhoA transcription by recognizing any one of five non-canonical E-box motifs within fragment C. To validate this notion, we mutated these non-canonical E-box motifs individually and used them in a reporter assay. We successfully generated full-length RhoA promoters with mutations in E-box 2, 4, 5 or 6 located within fragment C; a promoter with mutations in E-box 3 was not obtained because of its GC-rich content. The basal transcriptional activity of these promoters was not affected by the mutations ( Supplementary Information, Fig. S1c ). Although mutations in E-boxes 2 and 4 did not significantly affect the ability of Myc to induce RhoA transcription activation, mutations in either E-box 5 or E-box 6 impaired the effect of Myc on RhoA transcription activation (Fig. 1c) , suggesting that Myc may bind to E-box 5 and 6 to regulate RhoA transcription.
To corroborate this notion, we performed in vivo chromatin immunoprecipitation (ChIP) assays to address whether Myc binds to the RhoA promoter region surrounding E-boxes 5 and 6. The ChIP assay revealed that endogenous Myc binds to E-boxes 5 and 6, whereas Myc knockdown attenuated this effect (Figs 1d and 2b) . We found that Max was also present in this RhoA promoter, but the recruitment of Max to this RhoA promoter was only slightly affected by Myc knockdown (Fig. 1d) . Control experiments showed that RNA polymerase II bound to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter irrespective of Myc expression (Fig. 1e) .
Real-time PCR revealed that RhoA mRNA in Myc-null cells was much lower than in wild-type cells (Fig. 1f) . Similarly, Myc knockdown decreased RhoA mRNA expression, whereas Myc overexpression induced it (Fig. 1g, h) .
We examined the kinetics of RhoA transcription by using an inducible MycER system 20, 25 . MDA-MB-231 cells with stable MycER expression were generated, treated with 4-hydroxytamoxifen (4-OHT) to activate MycER proteins, and harvested for RhoA expression (Fig. 1i) . RhoA mRNA levels were induced after MycER activation by 4-OHT in a timedependent manner, similar to those encoding carbamoyl-phosphate synthetase 2, aspartate transcarbamylase and dihydroorotase (CAD) and ornithine decarboxylase (ODC), two known Myc target genes 26, 27 ( Fig. 1j) . These results suggest that Myc serves as a transcriptional factor to activate RhoA transcription. RhoA mediates Myc-regulated cell migration and invasion We next determined whether Myc levels are critical for RhoA protein expression and activity. Both RhoA protein expression and RhoA activity were greatly decreased in Myc-null cells, indicating that Myc regulates RhoA protein expression and in turn affects RhoA activity (Fig. 2a) . Similarly, knockdown of Myc expression profoundly decreased RhoA protein expression in cancer cells, whereas Myc overexpression promoted it (Fig. 2b, c) . RhoA protein expression was also induced after the MycER activation, in a time-dependent manner ( Supplementary Information,  Fig. S1d ). Because RhoA is critical in cell migration and invasion 3, 4 , we determined the function of Myc in these processes. Myc knockdown in cancer cells robustly attenuated cell migration and invasion, whereas Myc overexpression promoted these processes ( Fig. 2d, e ; Supplementary  Information, Fig. S1e, h) . RhoA knockdown or overexpression phenocopied the effects of Myc on cell migration and invasion ( Fig. 2f, g ; Supplementary Information, Fig. S1f, g, i) , raising the possibility that Myc may regulate these processes by affecting RhoA expression. In support of this notion we found that restoration of RhoA expression rescued a cell invasion defect in Myc-knockdown cells (Fig. 2h) . The effect of Myc and RhoA deficiency on cell migration and invasion was not due to their ability to regulate cell proliferation and apoptosis, because Myc and RhoA knockdown did not significantly affect either cell proliferation or apoptosis within 2 days, given that all our migration and invasion assays were performed within 24 h ( Supplementary Information, Fig. S2a-c) . However, Myc Relative mRNA level (percentage) (Skp2/GAPDH) knockdown significantly inhibited cell proliferation at later time points and also primary tumour formation ( Supplementary Information, Fig. S2a, d ), supporting its oncogenic functions 16, 17 . Our results identify RhoA as a critical effector for Myc-mediated cell migration and invasion.
Skp2 cooperates with Myc to promote RhoA transcription independently of SCF-Skp2 E3 ligase activity Although ubiquitylation is thought to regulate protein degradation, recent studies suggest that ubiquitylation also has a non-proteolytic role in the control of transcription 28, 29 . HectH9 and Skp2 E3 ligases have been shown to induce Myc ubiquitylation and to cooperate with Myc to induce a subset of target genes important for cell-cycle progression and proliferation [18] [19] [20] . To investigate whether Myc ubiquitylation is also important for Myc-mediated RhoA transcription, we examined the effect of HectH9 and Skp2 on RhoA transcription. HectH9 overexpression failed to promote RhoA transcriptional activation, protein expression and Myc-mediated RhoA transcription, although it induced Myc ubiquitylation ( Fig. 3a; Supplementary Information,  Fig. S3a, b ) 18 . Moreover, we found that HectH9 was not required for RhoA protein expression and the ability of Myc to induce RhoA transcription ( Supplementary Information, Fig. S3c, d ). These results suggest that a subset of Myc target genes such as RhoA are not regulated by HectH9 and HectH9-mediated Myc ubiquitylation. However, we found that RhoA transcription was induced by Skp2 overexpression, and a synergistic effect on RhoA transcription was observed on overexpression of Skp2 and Myc (Fig. 3a) . Skp2 is an F-box protein that forms a Skp2-SCF complex with Skp1, Cullin-1 and Rbx1 to constitute an E3 ligase activity, and its F-box domain is required for SCF-Skp2 E3 ligase activity and Skp2 oncogenic functions 30, 31 . Because Skp2 regulated Myc ubiquitylation ( Supplementary Information, Fig. S3e ), we wished to determine whether SCF-Skp2 E3 ligase activity is required for the effect of Skp2 on RhoA transcription. Consistent with the previous reports 19, 32 was our finding that the Skp2-LRR mutant devoid of the amino terminus and F-box domain failed to form a Skp2-SCF complex and lost its E3 ligase activity towards promoting the ubiquitylation of p27 and Myc ( Supplementary Information, Fig. S4a-c) , two well-known Skp2 substrates 19, 20, 30, 31 . Skp2-LRR synergized with Myc to activate RhoA transcription in the same way as wild-type Skp2 did (Fig. 3b) . This result suggests that SCF-Skp2 E3 ligase activity and Myc ubiquitylation induced by Skp2 are not critical for RhoA transcription.
We next determined whether Skp2-induced RhoA transcription requires Myc. The ChIP assay demonstrated that both endogenous Skp2 and Myc bind to the RhoA promoter, and Myc knockdown prevented Skp2 from binding to this promoter (Fig. 3c) , suggesting that Myc recruits Skp2 to the RhoA promoter to activate RhoA transcription. This notion was further supported by the fact that Skp2 failed to activate RhoA promoters with mutations in either E-box 5 or E-box 6, the region critical for Myc binding (Figs 1c and 3d ). Although Myc induced RhoA transcriptional activation in green fluorescent protein (GFP)-knockdown cells, it failed to activate RhoA transcription in Skp2-knockdown cells (Fig. 3e) , suggesting that Skp2 is required for Myc-mediated RhoA transcription. Consistent with the role of Skp2 in RhoA transcription was our finding that Skp2 −/− MEFs showed a profound decrease in RhoA mRNA levels, RhoA protein levels and RhoA activity (Fig. 3f, g ). Similarly, Skp2 knockdown markedly decreased RhoA levels, whereas Skp2 overexpression induced RhoA protein expression ( Our results therefore underscore the critical role of the Myc and Skp2 network in RhoA transcription and suggest that SCF-Skp2 E3 ligase activity is not required for this function.
Skp2 regulates cell migration and invasion by affecting RhoA expression
Skp2 overexpression is associated with cancer progression and metastasis 33, 34 , suggesting that Skp2 may be important in cancer cell migration, invasion and metastasis. Indeed, we observed that Skp2 −/− MEFs or Skp2-knockdown cells showed a marked decrease in cell migration and invasion ( Fig 30, 31, 34 . Similarly, Skp2 overexpression markedly promoted cell migration in the same way as Myc and RhoA overexpression did ( Fig. 4d; Supplementary Information, Fig. S1h, i) . Restoration of RhoA expression rescued both cell migration and invasion defects in Skp2 −/− MEFs and Skp2-knockdown cells ( Fig. 4a; Supplementary Information,  Fig. S5c, e) , suggesting that RhoA serves as a critical downstream effector for Myc and Skp2 in cell migration and invasion. The restoration of the Skp2-LRR mutant also rescued RhoA protein expression and the cell invasion defect in Skp2 −/− MEFs in the same way as wild-type Skp2 did (Fig. 4e) . Our results therefore suggest a novel E3 ligase-independent function for Skp2 in RhoA transcription and cell invasion.
Skp2 recruits p300 and Miz1 to the Myc transcriptional complex to induce RhoA transcription Because Skp2 is required for Myc-mediated RhoA transcription in an SCF E3 ligase-independent manner, it is very likely that Skp2 interacts with other co-regulators and recruits them to the Myc transcriptional complex for RhoA activation. p300 is known to serve as a coactivator for Myc on numerous Myc target genes, and the interaction between p300 and Skp2 has recently been unravelled 35 . To gain further insight into how Skp2 regulates RhoA transcription, we determined whether Skp2 interacts with p300 and recruits p300 to the Myc transcriptional complex. We found that Skp2 interacted with Myc and p300, and the Myc immunocomplex contained both Skp2 and p300 ( Supplementary  Information, Fig. S6a-c) . The endogenous Myc complex also consisted of Skp2, p300 and Max, and the presence of these proteins in the Myc immunocomplex was decreased on Myc knockdown ( Fig. 5a ; Supplementary Information, Fig. S6d ), suggesting that Myc forms a complex with Skp2, p300 and Max. Skp2 knockdown significantly decreased the interaction between Myc and p300 but not that between Myc and Max (Fig. 5b) .
As expected, we found that Skp2-LRR interacted with Myc and p300 and cooperated with them to activate RhoA transcription in the same way as wild-type Skp2 did ( Fig. 5c, d ; Supplementary Information,  Fig. S6d ). p300 could induce, and synergized with, Myc and Skp2 to activate RhoA transcription, whereas its knockdown profoundly a c decreased RhoA protein expression (Fig. 5d, e) . The ChIP assay revealed that endogenous p300 was also present in the RhoA promoter, and the recruitment of p300 to the RhoA promoter was impaired in Skp2-knockdown cells ( Fig. 5f; Supplementary Fig. S6e ). These results support the notion that Skp2 recruits p300 to the Myc complex to activate RhoA transcription independently of its SCF E3 ligase activity. Miz1 was originally identified as a Myc-interacting protein that causes cell growth arrest by inducing expression of the cell-cycle inhibitors p15 and p21 (refs 36-38) . In line with these reports [36] [37] [38] , we found that Miz1 knockdown promoted cancer cell growth ( Supplementary Information,  Fig. S2b) . We examined the effect of Miz1 on Myc-mediated RhoA transcription. We found that that Miz1 induced and synergized with Myc to activate RhoA transcription (Fig. 6a) . To further support the role of Miz1 in Myc-mediated RhoA transcription, we used the V394D mutant of Myc, which is defective in Miz1 binding, for the RhoA transcription assay 39 . MycV394D compromised the ability of Myc to induce RhoA transcription ( Fig. 6b; Supplementary Information, Fig. S6f, g ), suggesting that Miz1 is important in Myc-mediated RhoA transcription.
The ChIP assay revealed that endogenous Miz1 was also present in the same RhoA promoter as Myc, Max, Skp2 and p300 (Figs 1d, 3c and 6c; Supplementary Information, Fig. S6e) . As a control, we showed that Miz1, like Myc, was present in the p21 core promoter region 39 but not in the distal E-box1 region of the RhoA promoter (Fig. 6c) . Endogenous Miz1 was also present in the endogenous Myc-Skp2-p300 immunocomplex (Fig. 5a ). The recruitment of Miz1 to the Myc complex and the RhoA promoter relied partly on Skp2, because Skp2 knockdown decreased the ability of Miz1 to interact with Myc and its binding to the RhoA promoter (Figs 5f and 6d) . This result was partly explained by the fact that Skp2 was able to interact with Miz1 (Fig. 6e) . As a consequence, RhoA transcriptional activation induced by Myc, Miz1 and p300 was impaired in Skp2-knockdown cells (Fig. 6f) . Similarly, we found that the synergetic effect of Myc with p300 or Miz1 on RhoA transcription was diminished on Skp2 knockdown (Fig. 6f) . The Skp2-LRR mutant interacted with Miz1 and synergized with Miz1 and Myc to induce RhoA transcription in the same way as wild-type Skp2 did (Fig. 6e, g ). Similarly, Miz1 overexpression induced RhoA protein expression, whereas its knockdown decreased it ( Fig. 6h; Supplementary  Information, Fig. S6h ). Despite the fact that Miz1 overexpression causes cell-cycle arrest [36] [37] [38] , it promoted cell invasion (Fig. 6g) . Our results therefore support the notion that Skp2 induces RhoA transcription, cell migration and cell invasion by recruiting p300 and Miz1 to the Myc complex independently of its SCF-Skp2 E3 ligase activity.
The Myc-Skp2-Miz1 complex is critical for cancer metastasis
We used a well-established metastasis animal model to determine the role of the Myc-Skp2-Miz1 complex and RhoA in breast cancer metastasis [40] [41] [42] . Deficiency of Myc or Skp2 profoundly restricted breast cancer metastasis to the lung, whereas overexpression of Myc or Skp2 promoted it (Fig. 7a, b, d ; Supplementary Information, Fig. S7a ). Although Miz1 is thought to be a tumour suppressor whose knockdown enhances cell proliferation ( Supplementary Information, Fig. S2b ), Miz1 knockdown significantly suppressed cancer metastasis to the lung (Fig. 7c) . RhoA deficiency phenocopied metastasis defects in the knockdown of the Myc-Skp2-Miz1 complex (Fig. 7a) . Deficiency of Myc, Skp2 or Miz1 consistently decreased RhoA protein expression in metastatic breast tumours within the lung, whereas overexpression of Myc or Skp2 enhanced it ( Fig. 7d; Supplementary Information, Fig. S7 ). Our results underscore the critical role of the Myc-Skp2-Miz1 complex in RhoA expression, cell invasion and cancer metastasis.
We next determined whether Skp2 also shows SCF-Skp2 E3 ligaseindependent function in cancer metastasis. Skp2-LRR strikingly promoted breast cancer metastasis to the lung in the same way as wild-type Skp2 did, which correlated with its ability to induce RhoA expression in metastatic breast tumours in the lung (Fig. 7d) . However, Skp2-LRR compromised its effects on promoting cell-cycle progression, cell proliferation and primary tumour formation compared with wild-type Skp2 ( Supplementary Information, Fig. S8 ), supporting the current view of the SCF-Skp2 E3 ligase-dependent role in cell-cycle progression and tumorigenesis 30, 31, 34 . Accordingly, our results strongly support a novel SCF-Skp2 E3 ligase-independent role in cancer metastasis.
To gain further insight into how Skp2 regulates cancer metastasis, we monitored the kinetics of breast cancer metastasis to the lung by using bioluminescence imaging. We found that the circulation of breast cancer cells with control or Skp2 silencing to the lung was comparable 2 h (day 0) after the injection into the tail vein (Fig. 7e) , suggesting that Skp2 does not affect the arrival of breast cancer cells to the lung. However, the bioluminescence signal in the lung was decreased in Skp2 knockdown cells within the first week, and the profound decrease in bioluminescence signal was also observed at later time points ( Fig. 7e ; Supplementary Information, Fig. S9 ), indicating that Skp2 positively regulates the colonization of breast cancer cells in the lung and subsequent metastasis there. In support of the role of Skp2 in RhoA expression and cancer metastasis, we found that RhoA knockdown phenocopied the effects of Skp2 knockdown on these processes ( Fig. 7e; Supplementary  Information, Fig. S9 ). These results suggest that Skp2 and RhoA affect the colonization of breast cancer cells in the lung, in turn regulating cancer metastasis.
The Myc-Skp2-Miz1 complex is overexpressed and correlated with RhoA expression in metastatic human cancers Because Myc-Skp2-Miz1 overexpression is correlated with RhoA expression in vitro and these components are critical for cancer metastasis, we sought to determine whether there is a positive correlation between RhoA expression and the Myc-Skp2-Miz1 complex in human cancer samples. Analysing prostate cancer samples (64 cases), we found that the expression of RhoA (P = 0.015), Myc (P = 0.041), Skp2 (P = 0.001) and Miz1 (P = 0.016) was significantly correlated with prostate cancer metastasis compared with primary prostate cancer ( Fig. 8a, b; Supplementary Information, Fig. S10a ). RhoA expression was also significantly correlated with Myc (P = 0.024), Skp2 (P = 0.007) and Miz1 (P < 0.001) in prostate cancers ( Supplementary Information,  Fig. S10b ). We found that there was also a positive correlation between the components of the Myc-Skp2-Miz1 complex (for example Myc and Skp2 (P = 0.001), Myc and Miz1 (P < 0.001) and Skp2 and Miz1 (P < 0.001); Supplementary Information, Fig. S10b ). Our study therefore underscores the clinical relevance of the Myc-Skp2-Miz1 complex and RhoA expression in cancer metastasis.
DiSCuSSiOn
Our study provides the first clue as to how RhoA transcription is induced. We found that RhoA transcription is orchestrated by the Myc-Skp2-Miz1-p300 transcriptional complex. Knockdown or deficiency of these components impairs RhoA expression, resulting in defects in cell migration and invasion. This finding is further underscored by the important clinical observations that RhoA expression was positively correlated with the Myc-Skp2-Miz1 complex in metastatic prostate cancer, which may provide the relevant molecular mechanism by which RhoA overexpression occurs during cancer progression and metastasis.
Myc ubiquitylation by HectH9 and Skp2 has been shown to be critical for Myc target genes involved in cell-cycle progression and proliferation [18] [19] [20] . However, our study suggests that Myc ubiquitylation by these two E3 ligases is not required for RhoA gene expression. Although Myc is thought to display an oncogenic activity partly through antagonizing Miz1 transcriptional activity towards p21 and p15 gene expression, it has been unclear whether Miz1 has any impact on Myc transcriptional activation. The current dogma favours the notion of a mutual antagonism between the oncogenic Myc and the tumour suppressor Miz1 in gene regulation [15] [16] [17] 43 . Our results show that Miz1 synergizes with Myc to induce RhoA transcription, providing a new insight into the novel regulatory mechanism between Myc and Miz1. Although Miz1 overexpression causes cell-cycle arrest and inhibits cell proliferation [36] [37] [38] , we found that Miz1 cooperates with Myc to induce RhoA expression and cancer cell invasion and is required for cancer metastasis, which is consistent with our finding that Myc, Miz1 or RhoA overexpression are positively correlated with each other in metastatic cancer samples. Our study therefore reveals a previously unrecognized function of Miz1 in RhoA transcription, cell invasion and cancer metastasis.
Skp2 depends on SCF-Skp2 E3 ligase activity to exert its oncogenic activity towards the promotion of cell proliferation and tumorigenesis ( Supplementary Information, Fig. S8 ) 30, 31, 34 . Our study reveals a SCF-Skp2 E3 ligase-independent function for Skp2 in RhoA transcription, cell invasion and cancer metastasis. We propose a novel SCF E3 ligase-independent function for Skp2: specifically, that Skp2 recruits Miz1 and p300 co-regulators to the Myc complex, in turn facilitating RhoA transcription, cell invasion and cancer metastasis (Fig. 8c) . In contrast, SCF-Skp2 E3 ligase is required for the functioning of Skp2 in cell-cycle progression, proliferation and primary tumour formation by promoting the ubiquitylation and degradation of its substrates such as p27.
Our study reveals that the Myc-Skp2-Miz1 transcriptional complex is critical for RhoA transcription, cell migration and invasion, and cancer metastasis. Our findings, that overexpression of the Myc-Skp2-Miz1 complex promotes cancer cell invasion and metastasis whereas their deficiency restricts cancer metastasis, suggest that targeting this transcriptional complex may provide appealing therapeutic strategies for the treatment of cancer patients with metastasis. −/− mice were prepared as described previously. 293T, PC-3 (from ATCC), MDA-MB-231 and Rat1 cells (from M. J. M. Sedivy) were cultured in DMEM medium containing 10% fetal bovine serum (FBS). To clone Xp-Skp2, Skp2 was amplified by PCR using pcDNA3-Skp2 as a template and inserted into a pcDNA4-HisMax-TOPO vector (Invitrogen). To clone the full-length RhoA promoter, human RhoA promoter cDNA (nucleotides −1850 to +1, numbered relative to the transcription initiation site) was amplified from the genomic DNA of 293T cells and inserted into the pGL3 luciferase vector. The mutant RhoA promoters were generated by using the site-directed mutagenesis kit (Stratagene) in accordance with the manufacturer's standard procedure with the full-length RhoA promoter as a template. pBabe-Skp2 was generated by subcloning Skp2 into the EcoRI site of the pBabe vector. MSCV-PIG-RhoA and MSCV-Myc were generated by subcloning RhoA and c-Myc into the MSCV-PIG vector. RhoA reporter assay. 293T cells were transfected by using Lipofectamine 2000 (Invitrogen) for 48 h, and luciferase activity was measured by using the dual luciferase system (Promega). Each sample was analysed in triplicate and experiments were performed at least three times. The relative luciferase activity was calculated as a ratio between firefly luciferase activity and Renilla luciferase activity.
METHODS
Methods
Immunoprecipitation and immunoblotting. Immunoprecipitation (IP) and immunoblotting (IB) were performed essentially as described previously with some modifications. For protein-protein interaction, cells were lysed in E1A lysis buffer (250 mM NaCl, 50 mM HEPES pH 7.5, 0.1% Nonidet P40, 5 mM EDTA) containing a protease inhibitor cocktail (Roche). The following antibodies were used for IP, IB or immunofluorescence (IF): anti-Skp2 (IP, 1:250 dilution; IB, 1:1,000; Zymed), anti-Skp2 (IB, 1:1,000; Santa Cruz), anti-Skp1 (IB, 1:2,000; BD Transduction Lab), anti-Cul-1 (IB, 1:2,000; BD Transduction Lab), anti-Xpress (IP and IF, 1:500; IB, 1:5,000; Invitrogen), anti-HA (IB and IF, 1:1,000; Covance, Upstate), anti-β-actin (IB, 1:1,000; Sigma), anti-p27 (IP, 1:100; IB, 1:1,000; BD Transduction Lab), anti-Myc (IP, 1:100; IB, 1:1,000; Santa Cruz), anti-p300 (IP, 1:100; IB, 1:1,000; Santa Cruz), anti-Miz1 (IP, 1:100; IB, 1:1,000; Santa Cruz), antiHectH9 (IB, 1:1,000; Abcam) and anti-RhoA (IB, 1:2,000; Santa Cruz).
RhoA activity assay. RhoA activity assay was performed with the use of a Rho activation assay kit (Millipore) in accordance with the manufacturer's instructions. Equal amounts of protein were used to pull down active Rho with glutathione S-transferase-Rhotekin Rho-binding domain, which binds selectively to GTP-Rho and not to GDP-Rho. After precipitation, samples were analysed by western blotting with a specific anti-RhoA antibody.
Viral infection. Retroviral plasmids were transfected into Phoenix packing cells for 2 days, and the virus-containing medium was harvested and used to infect target cells. For lentiviral shRNA infection, 293T cells were co-transfected with Skp2, Myc, RhoA or GFP control shRNA with packing plasmids (deltaVPR8.9) and envelope plasmid (VSV-G) using Lipofectamine 2000 reagent in accordance with the manufacturer's instructions. RhoA-lentiviral shRNA-1 (5´-GAAAGCAGGTAGAGTTGGCTT-3´),ChIP assay. The ChIP assay was performed in accordance with the manufacturer's instructions (Upstate). A DNA-protein complex was sheared by sonication. A 1% portion of the sheared DNA-protein complex was kept as an input DNA sample. Anti-Skp2 (1:250, clone 8D9; Zymed), anti-Myc (1:100, clone N262; Santa Cruz), anti-Max (1:100, clone C17; Santa Cruz), anti-p300 (1:100, clone N15; Santa Cruz), anti-Miz1 (1:100, clone H190; Santa Cruz) and anti-RNA polymerase II (1:500, clone 6H5-3; Upstate) or normal mouse/rabbit IgG (1:500, Upstate and Sigma) were used for immunoprecipitation. Enrichment of promoter binding levels was analysed by real-time PCR, normalized by input, and expressed as a fold increase over the control. Primers used for real-time PCR were as follows: RhoA E-box5/6, 5´ -CTTCGCGTGCGTGAAGAGTTG-3´ and 5´-CATCCACTATTGCTCAGGAGC-3´ ; RhoA E-box1, 5´-GAGA-AGCCTTCCCTGACCACC-3´ and 5´ -GCTCACTAATCAGGGCATTCAT-3´ ; p21 core promoter, 5´-ACCGGCTGGCCTGCTGGAACT-3´ and 5´ -TCTGCC-GCCGCTCTCTCACCT-3´ . Quantified results are presented as means ± s.d.
In vivo ubiquitylation assay. The in vivo ubiquitylation assay was performed as described 44 . In brief, 293T cells were transfected with the indicated plasmids for 24 h, treated with 20 µM MG-132 for 6 h, and lysed with denaturing buffer (6 M guanidineHCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM imidazole). The cell extracts were then incubated with nickel beads for 3 h, washed, and subjected to western blot analysis.
Cell migration and invasion assays. The cell migration assay was performed in a 24-well transwell plate with 8-µm polyethylene terephthalate membrane filters (Falcon cell culture insert; Becton-Dickinson) separating the lower and upper culture chambers. In brief, MEFs, MDA-MB-231 cells and PC-3 cells were plated in the upper chamber at 10 4 , 5 × 10 4 and 10 5 cells per well, respectively, in serumfree DMEM. The bottom chamber contained DMEM with 10% FBS. MEFs and PC-3 cells were allowed to migrate for 18 h, whereas MDA-MB-231 cells were allowed to migrate for 6 h. After the incubation period, the filter was removed, and non-migrant cells on the upper side of the filter were detached with the use of a cotton swab. Filters were fixed with 4% formaldehyde for 15 min, and cells located in the lower filter were stained with 0.1% crystal violet for 20 min and three random fields were counted. Quantified results are presented as means ± s.d. The cell invasion assay was essentially similar to the cell migration assay, except that the membrane filter was precoated with diluted Matrigel (Matrigel:serumfree DMEM, 1:6) before the assay.
Immunohistochemistry and statistical analysis. Immunohistochemical analysis was performed on representative tissue blocks of primary prostatic adenocarcinomas from 64 patients. Among them, 37 patients presented with localized disease after follow-up for at least 5 years, and 27 patients developed metastatic disease either at diagnosis of adenocarcinoma or within 2 years. The sections were heated for epitope retrieval, quenched in 3% H 2 O 2 to abolish endogenous peroxidase, and then incubated with 10% normal horse serum to block non-specific immunoreactivity. The primary antibodies were detected with an EnVision kit (Dako) for RhoA (26C4, 1:200; Santa Cruz Biotechnology), Myc (9E10, 1:200; Zymed Laboratories), Skp2 (2C8D9, 1:100; Zymed Laboratories) and Miz-1 (1:400; Atlas Antibodies). To evaluate the expression of all markers, the percentage of tumour cells with moderate or strong nuclear and/or cytoplasmic immunoreactivity was recorded to obtain the labelling index for each case. The correlations between the four markers were calculated by using Pearson's correlation test, and the differences in the labelling indices of the markers tested between cases with and without metastatic disease were compared by using Student's t-test.
nature cell biology Metastasis assay. To study RhoA, Myc, Skp2 or Miz1 deficiency in a breast cancer metastasis model, MDA-MB-231 cells silenced with GFP, RhoA, Myc, Skp2 or Miz1 lentiviral shRNAs were injected into the tail veins of athymic female nude mice. After 12 weeks, mice (n = 5-7 for each group) were killed and lung tissues were analysed for the occurrence of metastasis. To study the role of overexpression of Myc, wild-type Skp2 and Skp2-LRR in metastasis, MDA-MB-231 cells were infected with retroviruses expressing empty vector, Myc, Skp2 or Skp2-LRR and selected with 2 µg ml −1 puromycin for 4 days. These viable cells were injected into the tail vein of athymic male nude mice. Eight weeks later, mice (n = 6-7 for each group) were killed and lung tissues were obtained for analysis of cancer metastasis. To study the kinetics of breast cancer metastasis to the lung, MDA-MB-231-Luc cells stably overexpresssed with luciferase gene silenced with GFP, Skp2 or RhoA shRNA were injected into the lateral tail vein (2 × 10 6 cells) of athymic female nude mice (seven mice for each group). For bioluminescence imaging, mice were anaesthetized and given 150 mg g −1 d-luciferin in PBS by intraperitoneal injection. At 5 min after injection, bioluminescence was detected with an IVIS imaging system and analysed with Living Image software (Xenogen). Cell growth, apoptosis and in vivo tumorigenesis assay. For the cell growth assay, 5 × 10 3 cells were seeded in 12 wells in triplicate, harvested, and stained with trypan blue on different days. Viable cells were counted directly under the microscope. For the apoptosis assay, cells were cultured for 2 days, harvested, labelled with fluorescein isothiocyanate-tagged Annexin-V, and followed by flow cytometry analysis. For the in vivo tumorigenesis assay, cells were injected subcutaneously into athymic female nude mice, tumour size was measured weekly with a calliper, and tumour volume was determined with the standard formula L × W 2 × 0.52, where L is the longest diameter and W the shortest diameter.
Primer sequences for real-time RT-PCR. Human CAD, 5´-CAGGTTT-GCCAGCTGAGGA-3´ (forward) and 5´-TGCCTGTCTCGGTACTGGTG-3´ (reverse); human ODC, 5´-TGTAGGAAGCGGCTGTAC-3´ (forward) and 5´-GCTAT GATTCTCACTCCAGAG-3´ (reverse); human RhoA, 5´-GAGC-ACACAAGGCGGGAG-3´ (forward) and 5´-CTTGC AGAGCAGCTCTCGTAG-3´ (reverse); human GAPDH, 5´-GATT CCACCCATGGCAAATTC-3´ (forward) and 5´-CTTC TCCATGGTGGTGAAGAC-3´ (reverse); mouse RhoA, 5´-GAGT TGGCTTTATGGGACAC-3´ (forward) and 5´-GAAAT-GCTTGACTTCTGGAGTC-3´ (reverse); mouse GAPDH, 5´-GACAAAA-TGGTGAAGGTCGGTG-3´ (forward) and 5´--3´ (reverse).
Statistical analysis.
Unless otherwise noted, data are presented as means ± s.d. of three or more independent results, and statistical significance was assessed by a two-tailed paired Student's t-test. P < 0.05 was considered significant. 
